Safety and Efficacy of Topiramate in Individuals With Cryptogenic Sensory Peripheral Neuropathy With Metabolic Syndrome: The TopCSPN Randomized Clinical Trial

A Gordon Smith,J Robinson Singleton,Adrienne Aperghis,Christopher S Coffey,Peter Creigh,Merit Cudkowicz,Robin Conwit,Dixie Ecklund,Janel K Fedler,Anna Gudjonsdottir,Peter Hauer,David N Herrmann,Marianne Kearney,John Kissel,Elizabeth Klingner,Adam Quick,Cathy Revere,Amro Stino,NeuroNEXT NN108 TopCSPN Study Team,Elias Sirja,Aaron Vinik,Amanda Peltier,Mamatha Pasnoor,Brian Callaghan,Daniella Maria Menichella,Chris Nance,Reza Seyedsadiadi,Mario Saporta,Lauren Phillips,Eroboghene Ubogu,Shawn Bird,Stefanie Geisler,Glenn Lopate,James Caress,Thomas Brannagan,Kelly Gwathmey,Erik Ortega,Tahseen Mozaffar,Mark Milstein,Dianna Quan,Janet Snowden,Julie Charles,Elizabeth Wood,Joan Mountain,Christine Annis,Debra Guntrum,Cynthia Gibson,Noreen Connolly,Steffen Behrens-Spraggins,Mariana Doudova,Candice Dolan,Amy Bartlett,Julie Agriesti,Carolina Casellini,Michael Bailey,Kelly Lowen,Tricia McKinney,Sally Furukawa,Alyssa Lackey,Tina Liu,Katheryn Jennens,Samantha Colgan,Amanda Rasnake,Meghan Stelzer,Courtney Graft,Tina Ward,Taylor Coffey,Cosette Burian,Monika Szela,Justine Houseman,Connie Casale,Jeri Sieren,Heena Olalde,Nicole Kressin,Loriane Brenner,Peter James,Claudia Maria Brito Pires,Natalie Grant,Wendy Levy,Julie Steele,Maria Paredes,Steven Hopkins,Amruta Joshi,William Thayer,Amy Conger,Jovana Valdez,Melanie Benge,Elizabeth Harders,Kelsey Moulton,Mengesha Teshome,Nikki Bauer,Kelly Streckfuss,Summer Harris,Jessyca Clemons,Karie Bond,Arreum Kim,Raisy Fayerman,Johana Gonzalez,Joyce Moran,Pranay Vissa,Bridget Wilkins,Nicole Turcotte,Stephanie Strong,Isela Hernandez,Marie Wencel,Diana Moyer,Melanie Meton,Elena Slabbekoorn,Rehana Rafi,Diane Capobianco,Connie Parido
DOI: https://doi.org/10.1001/jamaneurol.2023.3711
2023-12-01
Abstract:Importance: Cryptogenic sensory peripheral neuropathy (CSPN) is highly prevalent and often disabling due to neuropathic pain. Metabolic syndrome and its components increase neuropathy risk. Diet and exercise have shown promise but are limited by poor adherence. Objective: To determine whether topiramate can slow decline in intraepidermal nerve fiber density (IENFD) and/or neuropathy-specific quality of life measured using the Norfolk Quality of Life-Diabetic Neuropathy (NQOL-DN) scale. Design, setting, and participants: Topiramate as a Disease-Modifying Therapy for CSPN (TopCSPN) was a double-blind, placebo-controlled, randomized clinical trial conducted between February 2018 and October 2021. TopCSPN was performed at 20 sites in the National Institutes of Health-funded Network for Excellence in Neurosciences Clinical Trials (NeuroNEXT). Individuals with CSPN and metabolic syndrome aged 18 to 80 years were screened and randomly assigned by body mass index (<30 vs ≥30), which is calculated as weight in kilograms divided by height in meters squared. Patients were excluded if they had poorly controlled diabetes, prior topiramate treatment, recurrent nephrolithiasis, type 1 diabetes, use of insulin within 3 months before screening, history of foot ulceration, planned bariatric surgery, history of alcohol or drug overuse in the 2 years before screening, family history of a hereditary neuropathy, or an alternative neuropathy cause. Interventions: Participants received topiramate or matched placebo titrated to a maximum-tolerated dose of 100 mg per day. Main outcomes and measures: IENFD and NQOL-DN score were co-primary outcome measures. A positive study was defined as efficacy in both or efficacy in one and noninferiority in the other. Results: A total of 211 individuals were screened, and 132 were randomly assigned to treatment groups: 66 in the topiramate group and 66 in the placebo group. Age and sex were similar between groups (topiramate: mean [SD] age, 61 (10) years; 38 male [58%]; placebo: mean [SD] age, 62 (11) years; 44 male [67%]). The difference in change in IENFD and NQOL-DN score was noninferior but not superior in the intention-to-treat (ITT) analysis (IENFD, 0.21 fibers/mm per year; 95% CI, -0.43 to ∞ fibers/mm per year and NQOL-DN score, -1.52 points per year; 95% CI, -∞ to 1.19 points per year). A per-protocol analysis excluding noncompliant participants based on serum topiramate levels and those with major protocol deviations demonstrated superiority in NQOL-DN score (-3.69 points per year; 95% CI, -∞ to -0.73 points per year). Patients treated with topiramate had a mean (SD) annual change in IENFD of 0.56 fibers/mm per year relative to placebo (95% CI, -0.21 to ∞ fibers/mm per year). Although IENFD was stable in the topiramate group compared with a decline consistent with expected natural history, this difference did not demonstrate superiority. Conclusion and relevance: Topiramate did not slow IENFD decline or affect NQOL-DN score in the primary ITT analysis. Some participants were intolerant of topiramate. NQOL-DN score was superior among those compliant based on serum levels and without major protocol deviations. Trial registration: ClinicalTrials.gov Identifier: NCT02878798.
What problem does this paper attempt to address?